A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Parabilis Medicines, Inc.
Arcus Biosciences, Inc.
University of California, Irvine
City of Hope Medical Center
Institut Bergonié
Incyte Corporation
Peking Union Medical College Hospital
Toray Industries, Inc
NuCana plc
M.D. Anderson Cancer Center
ImmunityBio, Inc.
St. Petersburg State Pavlov Medical University
AstraZeneca
Endocyte
AIO-Studien-gGmbH
Mansoura University
Ziekenhuis Oost-Limburg
Washington University School of Medicine
UNICANCER
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Sanofi